Table 4.
Patients’ Characteristics in Matched Cohort.
| Variable | Sofosbuvir/Ledipasvir (N = 146) | Glecaprevir/Pibrentasvir (N = 73) | P Value | |
|---|---|---|---|---|
| Age (mean ± SD) | 55.9 ± 10.7 | 56.2 ± 10.5 | 0.9 | |
| Male | 87 (60%) | 44 (60%) | 0.9 | |
| Race | Black | 77 (53%) | 39 (53%) | 0.8 |
| White | 65 (45%) | 33 (45%) | ||
| Genotype | 1a | 109 (75%) | 56 (77%) | 0.8 |
| 1b | 36 (25%) | 17 (23%) | ||
| 4 | 1 (1%) | 0 (0%) | ||
| Duration | 9.9 ± 2.0 | 9.9 ± 2.0 | 0.9 | |
| SVR12 | 110 (96%) | 43 (100%) | 0.2 | |
| Liver stage | F0-1 | 21 (14%) | 9 (12%) | 0.9 |
| F2 | 52 (36%) | 25 (34%) | ||
| F3 | 12 (8%) | 8 (11%) | ||
| F4 | 55 (38%) | 29 (40%) | ||
| Diabetes mellitus | 19 (13%) | 9 (12%) | 0.9 | |
| Hypertension | 64 (44%) | 39 (53%) | 0.2 | |
| Diuretics | 26 (18%) | 12 (16%) | 0.8 | |
| ACEi/ARB | 36 (25%) | 27 (37%) | 0.06 | |
| Metformin | 8 (5%) | 4 (5%) | >0.9 | |
| NSAIDs | 29 (20%) | 11 (15%) | 0.4 | |
| Other nephrotoxic | 2 (1%) | 1 (1%) | >0.9 | |
| Creatinine pre-treatment (Mean ± SD) | 0.90 ± 0.22 | 0.91 ± 0.27 | 0.7 | |
| CKD | 2 | 134 (92%) | 62 (85%) | 0.2 |
| 3 | 9 (6%) | 7 (10%) | ||
| 4 | 3 (2%) | 4 (5%) | ||
Abbreviations:SD, standard deviation; SVR12, sustained virologic response at 12 weeks after treatment; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; HAART, highly active antiretroviral therapy; NSAIDs, nonsteroidal anti-inflammatory drugs; CKD, chronic kidney disease; Cr, creatinine.